Glucocorticoid-induced skeletal muscle atrophy is associated with upregulation of myostatin gene expression

Kun Ma,1,2 Con Mallidis,1 Shalender Bhasin,1 Vahid Mahabadi,1 Jorge Artaza,1,2 Nestor Gonzalez-Cadavid,1,2 Jose Arias,1 and Behrouz Salehian1

1Division of Endocrinology, Metabolism, and Molecular Medicine and 2Research Centers in Minority Institutions, Charles R. Drew University of Medicine and Science, Los Angeles, California 90059

Submitted 7 November 2002; accepted in final form 21 April 2003

Ma, Kun, Con Mallidis, Shalender Bhasin, Vahid Mahabadi, Jorge Artaza, Nestor Gonzalez-Cadavid, Jose Arias, and Behrouz Salehian. Glucocorticoid-induced skeletal muscle atrophy is associated with upregulation of myostatin gene expression. Am J Physiol Endocrinol Metab 285: E363–E371, 2003. First published April 29, 2003; 10.1152/ajpendo.00487.2002.—The mechanisms by which excessive glucocorticoids cause muscular atrophy remain unclear. We previously demonstrated that dexamethasone increases the expression of myostatin, a negative regulator of skeletal muscle mass, in vitro. In the present study, we tested the hypothesis that dexamethasone-induced muscle loss is associated with increased myostatin expression in vivo. Daily administration (60, 600, 1,200 μg/kg body wt) of dexamethasone for 5 days resulted in rapid, dose-dependent loss of body weight (−4.0, −13.4, −17.2%, respectively, P < 0.05 for each comparison), and muscle atrophy (6.3, 15.0, 16.6% below controls, respectively). These changes were associated with dose-dependent, marked induction of intramuscular myostatin mRNA (66.3, 450, 527.6% increase above controls, P < 0.05 for each comparison) and protein expression (0.0, 260.5, 318.4% increase above controls, P < 0.05). We found that the effect of dexamethasone on body weight and muscle loss and upregulation of intramuscular myostatin expression was time dependent. When dexamethasone treatment (600 μg·kg−1·day−1) was extended from 5 to 10 days, the rate of body weight loss was markedly reduced to −2% within this extended period. The concentrations of intramuscular myosin heavy chain type II in dexamethasone-treated rats were significantly lower (−43% after 5-day treatment, −14% after 10-day treatment) than their respective corresponding controls. The intramuscular myostatin concentration in rats treated with dexamethasone for 10 days returned to basal level. Concurrent treatment with RU-486 blocked dexamethasone-induced myostatin expression and significantly attenuated body loss and muscle atrophy. We propose that dexamethasone-induced muscle loss is mediated, at least in part, by the upregulation of myostatin expression through a glucocorticoid receptor-mediated pathway.

regulation; RU-486

GLUCOCORTICOIDS ARE COMMONLY USED in the treatment of a vast array of chronic inflammatory illnesses, such as systemic lupus erythematosus, sarcoidosis, rheumato
toid arthritis, and bronchial asthma (3, 4, 7). However, administration of high doses of glucocorticoids causes muscular atrophy in humans and animals (8, 31). Similarly, hypercortisolism has a major role in muscular atrophy in Cushing’s disease (2, 33). Many previous studies have suggested that glucocorticoids inhibit protein synthesis and stimulate protein degradation in skeletal muscle (2, 38, 39, 41, 42). Although a number of mechanisms have been put forward to explain the action of glucocorticoids on skeletal muscle (15, 16, 29, 49), the precise molecular mechanisms by which glucocorticoids induce muscle atrophy are still not well understood.

Myostatin, formerly known as growth and differentiation factor 8, a member of the transforming growth factor-β superfamily, is an important negative regulator of skeletal muscle mass. Disrupted myostatin gene expression, either by gene targeting in mice or as a consequence of naturally occurring mutations in cattle, is associated with increased skeletal muscle mass resulting from muscle fiber hyperplasia as well as hypertrophy (17, 24, 25, 30, 32). Conversely, increased serum myostatin concentration is associated with a loss of skeletal muscle mass in men with the AIDS wasting syndrome (11). Increases in myostatin expression have also been reported in experimental animals after exposure to microgravity during space flight (22) and after hindlimb suspension (6, 48). We (44) and other investigators (45) have demonstrated that recombinant myostatin protein inhibits C2C12 muscle cell proliferation and protein synthesis in vitro. The mechanisms that regulate myostatin gene expression remain poorly understood.

To investigate the regulation of myostatin gene expression, we recently cloned and characterized the 5’-upstream regulatory region of the human myostatin gene and found that the promoter contains a number of response elements important for muscle growth, including seven putative glucocorticoid response elements (GREs). We also demonstrated that dexamethasone dose-dependently increases endogenous myostatin transcription in C2C12 myocytes through a glucocorticoid receptor-mediated mechanism (1, 26).

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
These findings led us to postulate that the increase in myostatin gene expression by glucocorticoids might contribute to the pathogenesis of glucocorticoid-induced skeletal muscle atrophy. In the present study, we tested this hypothesis in vivo in a rat model. First, we determined the effects of graded doses of dexamethasone on intramuscular myostatin gene expression. Second, we investigated the time course of dexamethasone effect on intramuscular myostatin gene expression. Finally, we examined whether the effects of dexamethasone on myostatin mRNA and protein can be reversed by concomitant administration of a glucocorticoid antagonist, RU-486.

MATERIALS AND METHODS

Animal care and experimental treatments. Male Sprague-Dawley rats, 10–12 wk of age, with initial body weights ranging from 250 to 420 g, were purchased from Harlan Laboratories. Each animal was housed individually in controlled environmental conditions (temperature 22°C, 12:12-h light-dark cycle period starting at 6:00 AM) and provided standard laboratory rodent chow and water. All experimental procedures on animals were approved by the Institutional Animal Care and Use Committee of the Charles R. Drew University of Medicine and were in accordance with National Institutes of Health guidelines for humane treatment of laboratory animals.

Study 1. We examined effects of different doses of dexamethasone administered intraperitoneally for 5 days on body weight, skeletal muscle weight, and intramuscular myostatin protein and mRNA expression. Sixty adult male rats were divided into six groups with even initial body weight distribution in each group. Three randomly selected groups, I, II, and III, received intraperitoneal injections of 1 ml of dexamethasone (Sigma) dissolved in saline (0.85% NaCl) at daily doses of 60, 600, and 1,200 μg/kg body wt, respectively. These doses were selected because administration of dexamethasone at 600 μg/kg body wt has been shown previously to cause muscle atrophy (12, 40). For each dose experiment, there was a control group also randomly chosen from the three groups. Thus each control animal, receiving a daily intraperitoneal injection of 1 ml of saline (vehicle, 0.85% NaCl) had a pair mate (matched by body weight) in the corresponding group receiving dexamethasone treatment. All dexamethasone-treated animals were allowed free access to food and water. Dexamethasone treatment has been reported to decrease food intake (40). It is not known whether food intake can affect myostatin expression independently in animals; therefore, each control animal was pair fed the same amount of food as was consumed by its dexamethasone-treated pair mate during the previous day.

Study 2. Forty rats were divided into four groups with equal total body weight distribution in each group. Two groups were randomly selected to receive dexamethasone treatment (600 μg/kg body wt) intraperitoneally daily for either 5 days (group I) or 10 days (group II), respectively. The 600 μg/kg body wt dose was selected because this dose resulted in significant loss of muscle mass in study 1. The remaining animals, used as controls, were randomly assigned to one of the two dexamethasone-treated groups. Each control animal, receiving daily intraperitoneal injection of vehicle (1 ml of 0.85% NaCl) had a pair mate (matched by body weight) in the corresponding dexamethasone-treated group. All dexamethasone-treated animals were allowed free access to food and water. Each control animal was allowed free access to water but pair fed the same amount of food as was consumed by its dexamethasone-treated pair mate during the previous day.

Study 3. We examined whether the glucocorticoid receptor antagonist RU-486 could inhibit the effect of dexamethasone on intramuscular myostatin protein and mRNA expression. In this experiment, 50 rats were divided into five groups with an even distribution of initial body weight in each group. The animals were randomly selected for receiving the following treatments for five consecutive days. Group Dex received dexamethasone (600 μg/kg body wt) daily; group Dex/RU-486 received dexamethasone (600 μg/kg body wt) and RU-486 (1,313 μg/kg body wt or 2× molarity of dexamethasone) daily; group RU-486 received RU-486 (1,313 μg/kg body wt) daily; control group FC was given daily saline injections and pair fed; and control group PC was given daily saline injections and free access to food. Animals in groups Dex and FC were allowed free access to the food and water, and their food intakes were recorded daily. Individuals in groups Dex/RU-486, RU-486, and PC were allowed free access to water but were pair fed with the same amount of food as was consumed by their dexamethasone or saline- or pair fed mates. In all studies, each individual’s body weight was recorded daily.

Muscle collection and calculation of change of muscle mass. After each experimental protocol, animals were killed by CO2 asphyxiation. The muscles of the gastrocnemius and flexor digitorum superficialis (G/FDS) complex from both legs were excised together, weighed on an analytical balance, and quickly frozen on dry ice and stored at −80°C for subsequent RNA and protein extractions. Although we tried to group animals with an even distribution of initial body weight, there were still minor differences in the averages of initial total body weights among experimental groups. Because the wet muscle weight can be measured only at the end of each experiment, we adjusted the average muscle weight of each experimental group by multiplying its measured average muscle weight (MW) by the ratio of its initial average body weight (BW) vs. that of the control group, i.e.

\[
\text{adjusted MW}_{\text{Group A}} = \frac{\text{measured MW}_{\text{Group A}} \times (\text{BW}_{\text{control}} \div \text{BW}_{\text{Group A}})}{
}

Northern blot analysis. Total RNA was extracted from the G/FDS muscle complex with TRIzol (GIBCO-BRL), following the instructions provided by the manufacturer. The extracted RNA pellets were dissolved in diethyl pyrocarbonate-treated water. After the concentrations were determined by a spectrophotometer at 260 nm, all RNA samples were kept at −80°C until use. To determine the relative abundance of myostatin and the reference gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNAs, 25 μg of heat-denatured total RNA for each muscle were electrophoresed (4 V/cm for 4 h) on a 0.8% agarose denaturing gel prepared in MOPS [40 mM 3-(N-morpholino)-2-hydroxypropanesulfonic acid], 10 mM sodium acetate, 1 mM EDTA, and 6.6% formaldehyde (all from Sigma). The RNA was transferred to a Hybond-XL nylon membrane (Amersham) by overnight capillary action in 20× SSC (3 M NaCl + 0.3 M Na3citrate, pH 7.0). Membranes were treated with ultraviolet cross-link (UV Stratelinker 1800; Stratagene) at 70,000 μJ, as recommended by the manufacturer. Membranes that carried the RNA samples were first prehybridized in hybridization buffer (5× Denhardt’s, 6× SSC, 2.5% SDS, and 100 μg/ml denatured, sonicated salmon sperm DNA, 5 ml/100 cm² filters) in hybridization bottles at 60°C for ≥2 h. DNA probes were radiolabeled by random priming with [α-32P]dCTP (ICN) with a High Prime kit (Roche), following the manufacturer’s instructions.
For myostatin mRNA detection, a rat myostatin cDNA fragment of 748 bp (corresponding to nt 178–925) was used as the probe. For GAPDH mRNA detection, a rat GAPDH cDNA fragment of 1.2 kb was used as the probe.

A radiolabeled probe was boiled for 5 min before being added to the prehybridized membranes at 60°C. After being incubated with the probe overnight at 60°C, the membranes were washed (in SSC 0.1% SDS at 60°C) to the desired stringency by reducing the SSC concentration. The membranes were then exposed to Kodak Biomax film for 2–5 days at –80°C to visualize bands corresponding to myostatin and GAPDH transcripts. Concentrations of myostatin and GAPDH mRNA were quantified by densitometry scanning (Fluor-s Multiimager; Bio-Rad, Hercules, CA). The uniformity of loadings was adjusted by the optical density (OD) of the GAPDH band.

**Western blot analysis.** Protein was extracted from G/FDS complex by means of a denaturing-reducing lysis buffer containing 1% SDS, Tris-HCl, and a 1:20 dilution of β-mercaptoethanol. Samples (40 μg each) were heat denatured (95°C for 5 min), electrophoretically separated using 12% Tris-glycine polyacrylamide gels (ReadyGel; Bio-Rad), and the proteins were visualized using Coomassie brilliant blue staining. The electrophoretically separated samples were then transferred to a nitrocellulose membrane (Hybond-ECL; Amersham) and immunodetected using the previously described procedure with the myostatin polyclonal antibody “B” (11). An anti-rabbit-IgG secondary antibody linked to horse-radish peroxidase (HRP) was used. Blots were developed with an enhanced chemiluminescent substrate for HRP and exposed to film (ECL Hyperfilm; Amersham). To adjust the protein sample loading, the membranes were stripped by incubating them in stripping buffer (100 mM β-mercaptoethanol, 2% SDS, 62.5 mM Tris-HCl, pH 6.7) at 50°C for 30 min and then reprobing them with a rat monoclonal antibody for GAPDH. The concentrations of myostatin and GAPDH proteins were quantified by densitometry scanning (Fluor-s Multiimager). The uniformity of loadings was adjusted by the OD of the GAPDH band.

**Separation and quantitation of MHC isoforms.** The MHC isoforms of myofibrils were separated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) according to the method developed by Talmadge and Roy (43). Each gel was composed of two continuous parts, stacking gel (4% acrylamide, 30% glycerol) and separating gel (8% acrylamide, 30% glycerol). SDS-PAGE was run at a constant voltage of 70 V at 4°C for 24 h. The gel was then stained with Coomassie blue. The concentrations of the MHC isoforms were quantified by densitometry scanning (Fluor-s Multiimager).

**Statistical analysis.** All data are reported as means ± SE. All statistical tests were performed using the Jandel SigmaStat statistical software package. 

### Table 1. Dexamethasone dose effects on body weight and wet muscle mass

<table>
<thead>
<tr>
<th>Group (n)</th>
<th>Dex Treatment, μg/kg • day</th>
<th>Body Weight</th>
<th>Dex-Induced G/FDS Weight Changes, %</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>C</td>
<td>367.7 ± 5.0</td>
<td>0.54 ± 0.44</td>
</tr>
<tr>
<td>(2 × 10)</td>
<td>60</td>
<td>369.4 ± 4.9</td>
<td>354.5 ± 5.2</td>
</tr>
<tr>
<td></td>
<td>C</td>
<td>379.9 ± 4.4</td>
<td>375.3 ± 3.5</td>
</tr>
<tr>
<td>II</td>
<td>C</td>
<td>374.5 ± 4.9</td>
<td>325.0 ± 4.1</td>
</tr>
<tr>
<td>(2 × 10)</td>
<td>600</td>
<td>378.3 ± 5.1</td>
<td>361.2 ± 5.1</td>
</tr>
<tr>
<td></td>
<td>C</td>
<td>381.7 ± 5.2</td>
<td>314.9 ± 5.6</td>
</tr>
<tr>
<td>III</td>
<td>C</td>
<td>383.8 ± 5.1</td>
<td>361.2 ± 5.1</td>
</tr>
<tr>
<td>(2 × 10)</td>
<td>1,200</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Values are expressed as means ± SE. C, control; G/FDS, gastrocnemius and flexor digitorum superficialis muscle complex. *Dose of dexamethasone (Dex) per kg body wt daily; †adjusted value (see MATERIALS AND METHODS). Statistical analysis was carried out by 2-way ANOVA and Tukey’s test. *Significantly different from corresponding pair-fed group (P < 0.05); †significantly different from Dex (60 μg) dose group (P < 0.05).

**RESULTS**

**Study 1: effects of 5-day dexamethasone treatment on body and muscle weight.** Food intake decreased markedly in animals, particularly in the first 3 days after dexamethasone-treatment was initiated. The average food intakes of rats from each dexamethasone-treated group (60, 600, and 1,200 μg/kg body wt) on the day after the third dexamethasone injection were 19, 43, and 54% less than what they had eaten on the day before the dexamethasone treatment (data not shown).

**Administration of dexamethasone caused a progressive, dose-dependent loss of body weight in rats (Table 1).** The mean body weight reductions from baseline in dexamethasone-treated rats in groups I, II, and III (−4.0 ± 0.4, −13.4 ± 0.3, and −17.2 ± 0.4%, respectively) were significantly greater than those in the corresponding pair-fed controls (0.5 ± 0.4, −1.2 ± 0.3, and −4.5 ± 0.4%, respectively, P < 0.05; Table 1). The loss of body weight in pair-fed controls was apparently due to the restriction of their food intake.

The mean mass of the G/FDS complex was significantly lower in dexamethasone-treated rats than that in pair-fed controls within each dose group (Table 1). The rats treated with 600 and 1,200 μg/kg body wt daily had significantly lower muscle mass than those treated with the 60 μg/kg body wt (P < 0.05 for each comparison). As shown in Table 1, the losses of wet weight of G/FDS complex in dexamethasone-treated rats from groups I, II, and III were significantly (6.3 ± 0.4, 15.0 ± 0.3, and 16.6 ± 0.4%, respectively, all P <
0.05) higher than those of their corresponding pair-fed controls. Because the 600 μg/kg body wt dose produced near-maximal loss of muscle mass, we selected this dose in the subsequent time course experiments.

Dexamethasone treatment increases intramuscular myostatin gene expression. To determine whether dexamethasone administration affects myostatin expression in skeletal muscle from rats, we measured myostatin protein and mRNA concentrations in the G/FDS complex. The intramuscular myostatin mRNA concentrations, indicated by the abundance of a 2.9-kb transcript by Northern blot analysis, were significantly higher in dexamethasone-treated animals than in the corresponding pair-fed controls (P < 0.01). The dexamethasone-induced increase in myostatin mRNA expression in rats was dose dependent. In rats that received five consecutive daily injections of dexamethasone at 60, 600, or 1,200 μg/kg body wt, the myostatin mRNA expression in the G/FDS complexes was 66.3 ± 0.60, 450 ± 72.4 (P < 0.01), and 527.6 ± 79.8% (P < 0.01) higher, respectively, compared with their corresponding pair-fed controls (Fig. 1). Similarly, dexamethasone treatment also dose-dependently increased intramuscular myostatin protein expression. The myostatin protein expression, indicated by the abundance of a 30-kDa immunoreactive band by Western blot analysis in dexamethasone-treated rats at 600 or 1,200 μg/kg body wt, was 260.5 ± 22.3% (P < 0.01) or 318.4 ± 44.8% (P < 0.01) higher than that in their corresponding controls (Fig. 1). In contrast, rats treated with 60 μg/kg body wt dexamethasone showed no significant difference in myostatin protein expression compared with controls (Fig. 1). The sizes of the myostatin mRNA transcript and myostatin immunoreactive band detected in this study are consistent with the previously reported findings (6, 11, 48).

Study 2: time course of dexamethasone’s effects on body and muscle weight and intramuscular myostatin gene expression. To investigate whether extension of dexamethasone treatment would affect muscle weights and intramuscular myostatin protein and mRNA expression, we treated the rats with a daily injection of 600 μg/kg body wt dexamethasone for either 5 days (group I) or 10 days (group II). Again, dexamethasone administration induced a greater loss of body weight in both groups compared with their corresponding pair-fed controls. The average body weight changes in dexamethasone-treated rats from groups I and II, compared with their initial body weights, were −13.4 ± 0.6% (P < 0.05) and −15.3 ± 0.9% (P < 0.05), respectively. In contrast, the body weight changes of their corresponding pair-fed controls were −1.21 ± 1.0 and 0.42 ± 0.8%, respectively. However, the dexamethasone-induced changes in body weights between animals treated for 5 days and for 10 days were not significantly different from each other.

Overall, the average wet weights of G/FDS complex in dexamethasone-treated rats were 13.9 ± 0.71 and 16.5 ± 1.2% lower after 5 and 10 days of treatment compared with their pair-fed controls (P < 0.05 for each of the two comparisons). However, the wet weights of the G/FDS complex in rats treated with dexamethasone for 5 days (4.0 ± 0.2 g) were not significantly different from those in rats treated for 10 days (3.9 ± 0.3 g; Table 2). Interestingly, rats treated with dexamethasone for 5 days showed a marked de-
increase of 42.6% ($P < 0.05$) in the concentration of MHC II(A, X, B) isoforms in the G/FDS complex compared with the pair-fed controls. However, the concentration of MHC II(A, X, B) isoforms in animals treated with dexamethasone for 10 days was only 14.0% ($P < 0.05$) lower than that in the pair-fed controls (Fig. 2). No significant change was detected for MHC I in either dexamethasone-treated group.

As expected, the intramuscular myostatin mRNA expression in rats treated with dexamethasone for 5 days was (densitometry intensity reading 32.3 ± 1.5) significantly (4.50-fold, $P < 0.01$) higher than that (densitometry intensity reading 5.9 ± 1.4) in their pair-fed controls. The myostatin protein expression in these rats was (densitometry intensity reading 19.2 ± 1.0; Fig. 3). However, after 10 days of treatment, intramuscular myostatin protein concentrations were not significantly different between the control and dexamethasone-treated rats (6.3 ± 1.5 vs. 5.8 ± 1.5, $P = 0.82$ for mRNA and 6.0 ± 1.1 vs. 5.7 ± 1.0, $P = 0.86$ for protein; Fig. 3).

### Study 3: RU-486 inhibits dexamethasone’s effect on body and muscle weights and myostatin gene expression.

RU-486 is known to antagonize the effects of glucocorticoids by binding to the glucocorticoid receptors (20, 21, 28). To determine whether RU-486 antagonizes the effects of dexamethasone on myostatin mRNA and protein expression in vivo, we divided rats into five groups of equal body weight distribution. Three randomly selected groups were treated with dexamethasone (600 μg/kg body wt), dexamethasone (600 μg/kg body wt) plus RU-486 (1,313 μg/kg body wt), or RU-486 (1,313 μg/kg body wt) alone, respectively, for 5 days. To determine whether restriction of food intake could influence myostatin expression, we set up two groups of animals as controls, the pair-fed control (PC) and the free-access-to-food control (FC). Animals from both groups were given daily intraperitoneal injections of the vehicle (0.85% NaCl). The animals were killed after five consecutive daily treatments. Changes in their body weight, G/FDS mass, and myostatin gene expression were analyzed.

As shown in Table 3, animals in the FC group gained on average 7.8 ± 0.2% in body weight ($P < 0.05$) compared with their initial body weight, whereas the PC group lost 1.2 ± 0.3% ($P < 0.05$) in body weight. Dexamethasone-treated rats showed a much greater loss in body weight (−13.4 ± 0.3%, $P < 0.05$) compared with the PC group. Interestingly, Dex/RU-486 animals had significantly fewer losses in body weight (−6.4 ± 0.25%, $P < 0.05$) than those treated with dexamethasone alone, even though both groups of rats were fed the same amount of food. The change of body weight in the RU-486 group showed no significant difference from that in the PC group (Table 3).

The changes of body weights in the animals were mirrored by the wet muscle weights of each corresponding group. The average wet weight of G/FDS complex of the dexamethasone-treated rats (3.8 ± 0.1 g) was significantly lower than those of groups FC (4.9 ± 0.1 g, $P < 0.05$), PC (4.5 ± 0.1 g, $P < 0.05$), Dex/RU-486 (4.1 ± 0.1 g, $P < 0.05$), and RU-486 (4.5 ± 0.2, $P < 0.05$), respectively. There was no significant difference between the weights of wet G/FDS complex in the PC rats and those treated with RU-486 alone (Table 3).

To determine whether RU-486 could alter the dexamethasone-induced increase in intramuscular myostatin expression in animals, we examined the mRNA and protein expression in the G/FDS complex from these

### Table 2. Dexamethasone time course effects on body weight and weight and wet muscle mass

<table>
<thead>
<tr>
<th>Group (n)</th>
<th>Treatment, days</th>
<th>Body Weight</th>
<th>Dex-Induced Changes, %Initial, g Changes, %</th>
<th>G/FDS Weight, g</th>
<th>G/FDS Weight Changes, %</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>C(5)</td>
<td>335.8 ± 14.0</td>
<td>−1.21 ± 0.6</td>
<td>4.61 ± 0.2</td>
<td>0</td>
</tr>
<tr>
<td>(2 × 10)</td>
<td>Dex(5)</td>
<td>339.4 ± 14.9</td>
<td>−13.4 ± 0.7</td>
<td>3.91 ± 0.3</td>
<td>−15.1 ± 0.7</td>
</tr>
<tr>
<td>II</td>
<td>C(10)</td>
<td>336.2 ± 14.2</td>
<td>0.42 ± 0.8</td>
<td>4.67 ± 0.3</td>
<td>0</td>
</tr>
<tr>
<td>(2 × 10)</td>
<td>Dex(10)</td>
<td>338.7 ± 14.7</td>
<td>−15.2 ± 0.9</td>
<td>3.90 ± 0.3</td>
<td>−16.5 ± 1.2</td>
</tr>
</tbody>
</table>

Values are expressed as means ± SE. *Dex at 600 μg/kg body wt daily; †adjusted value (see MATERIALS AND METHODS). Statistical analysis was carried out by 2-way ANOVA and Tukey’s test. *Significantly different from corresponding pair-fed group ($P < 0.05$).
animals by using Northern and Western blot analyses. As displayed in Fig. 4, we found no significant difference in the intramuscular myostatin mRNA expression among animals from Groups FC, PC, and RU-486 (densitometry intensity readings 5.9 ± 0.9, 5.8 ± 0.9, and 5.6 ± 1.0, respectively, P < 0.05). The intramuscular myostatin mRNA expressions were 4.5-fold higher in dexamethasone-treated rats compared with their pair-fed controls (densitometry intensity reading 32.3 ± 1.6 vs. 5.8 ± 0.2, P < 0.01). The action of dexamethasone treatment on myostatin mRNA expression was effectively nullified by RU-486 administration, as the intramuscular myostatin mRNA expression in Dex/RU-486 rats (densitometry intensity reading 6.4 ± 1.0, P < 0.05) showed no significant difference compared with that in groups PC or FC (Fig. 4A).

Similarly, there was no significant difference in the intramuscular myostatin protein expression among animals from the FC, PC, and RU-486 groups (densitometry intensity readings 5.3 ± 0.3, 5.3 ± 0.2, and 5.2 ± 0.2, P < 0.05). The intramuscular myostatin protein expression in the dexamethasone-treated rats (densitometry intensity reading 19.2 ± 1.4, P < 0.01) was significantly higher than those in groups FC (5.3 ± 0.2, P < 0.05), PC (5.3 ± 0.2, P < 0.05), and RU-486 (5.2 ± 0.2, P < 0.05). Again, the dexamethasone-induced increase in myostatin protein expression was completely blocked by RU-486, because the myostatin protein expression (densitometry intensity reading 5.4 ± 1.0, P < 0.01) in animals concurrently administered dexamethasone plus RU-486 showed no significant difference from that in the PC group (Fig. 4B).

Table 3. Effects of dexamethasone plus RU-486 on body weight and wet muscle mass

<table>
<thead>
<tr>
<th>Treatment Group (n)</th>
<th>Initial, g</th>
<th>Final, g</th>
<th>Changes, %</th>
<th>G/PDS Weight, g</th>
<th>Dex-Induced G/PDS Weight Changes, %</th>
</tr>
</thead>
<tbody>
<tr>
<td>FC(10)</td>
<td>329.7 ± 16.3</td>
<td>355.5 ± 16.6</td>
<td>7.84 ± 0.18</td>
<td>4.91 ± 0.12</td>
<td>0</td>
</tr>
<tr>
<td>PC(10)</td>
<td>332.1 ± 17.7</td>
<td>328.2 ± 16.1</td>
<td>−1.2 ± 0.29</td>
<td>4.53 ± 0.10</td>
<td>0</td>
</tr>
<tr>
<td>Dexa(10)</td>
<td>322.6 ± 18.5</td>
<td>281.6 ± 17.2</td>
<td>−13.4 ± 0.29</td>
<td>3.8 ± 0.08b</td>
<td>−16.7 ± 0.14a</td>
</tr>
<tr>
<td>Dexa/RU-486(10)</td>
<td>326.2 ± 15.3</td>
<td>305.3 ± 17.1</td>
<td>−6.4 ± 0.25b</td>
<td>4.2 ± 0.13b</td>
<td>−7.3 ± 0.13a</td>
</tr>
<tr>
<td>RU-486c(10)</td>
<td>328.0 ± 14.7</td>
<td>324.4 ± 14.4</td>
<td>−1.1 ± 0.21</td>
<td>4.52 ± 0.16b</td>
<td>0</td>
</tr>
</tbody>
</table>

Values are expressed as means ± SE. FC, controls with free access to food; PC, pair-fed control; Dexa/RU-486, Dex plus RU-486. *Dex at 600 μg per kg body weight daily; **adjusted value (see MATERIALS AND METHODS). †RU-486 at 1,313 μg per kg body weight daily. Statistical analysis was carried out by 1-way ANOVA and Tukey’s test. *Significantly different from corresponding pair-fed group (P < 0.05).
DISCUSSION

Our study, although confirming previous observations that dexamethasone treatment leads to a dose-dependent loss of total body weight and skeletal muscle mass (2, 38, 39, 41, 42), is the first to demonstrate that this loss is associated with a dose-dependent upregulation of intramuscular myostatin mRNA and protein expression in vivo. These increases in intramuscular myostatin protein and mRNA concentrations were pronounced after 5 days of the treatment; however, the hyperexpression was not sustained, in either myostatin mRNA or protein expression, when treatment was extended to 10 days. Coinciding with the changes in myostatin expression, a marked decrease was found in MHC II protein expression. This decline of MHC expression was particularly obvious on day 5 of treatment, when myostatin expression was at its peak. Unlike myostatin, the decline in MHC II expression was maintained after 10 days of treatment, albeit at a decreased rate (14% compared with the 42.6% after 5 days). The addition of the potent glucocorticoid receptor antagonist RU-486 reversed the dexamethasone-induced hyperexpression of intramuscular myostatin, suggesting that the glucocorticoid’s influence on myostatin expression may be mediated through glucocorticoid receptor-mediated mechanisms.

Because loss of body weight during dexamethasone administration is largely attributed to skeletal muscle atrophy (10, 12, 39, 41), it was not surprising that the reduction in total body weight found in our dexamethasone-treated rats was proportionately less than the associated loss of G/FDS mass. The mechanism(s) by which glucocorticoids induce such catabolic and anti-anabolic effects on muscle remains unclear. Previous studies have shown that glucocorticoids promote protein degradation and impair protein synthesis, which result in muscle atrophy (2, 10, 12, 39, 41); however, the precise molecular mechanisms of these actions are yet to be elucidated.

A large body of emerging data suggests that myostatin is an important negative regulator of skeletal muscle mass (11, 17, 30, 32, 36, 37, 44, 45). Disruption of myostatin gene expression is associated with dramatic increases in skeletal muscle mass due to muscle fiber hyperplasia and/or hypertrophy (13, 17, 30, 32). Conversely, increased myostatin levels are associated with loss of skeletal muscle mass in conditions as disparate as AIDS wasting syndrome (11), exposure to microgravity during space flight (22), and hindlimb suspension (6, 48). Glucocorticoid-induced protein degradation resulting in muscle atrophy is known to occur predominantly in fast-twitch muscle fibers (MHC IIB), (9, 39, 47). Interestingly, myostatin gene expression appears to be much higher in muscles (e.g., G/FDS complex and extensor digitorum longus), which are mainly composed of fast-twitch fibers, than in those composed of slow-twitch fibers (e.g., soleus) (6, 18, 48). Our previous in vitro observations that recombinant myostatin protein inhibits muscle cell proliferation and protein synthesis (36, 37, 44, 45) suggest that it may have an antianabolic effect.

Previously, we identified multiple putative GREs in the human myostatin gene (26) and demonstrated that, in vitro, dexamethasone dose-dependently upregulated endogenous myostatin mRNA and protein expression by increasing myostatin gene transcription.
(1, 26). Our present in vivo observation emulates the previous finding (i.e., dexamethasone treatment resulted in significant dose-dependent increase in myostatin expression and a rapid decline of G/FDS mass), suggesting that dexamethasone-induced muscle atrophy is also associated with the upregulation of myostatin expression.

RU-486 inhibits glucocorticoid receptor binding and thus prevents dexamethasone-induced muscle atrophy (14, 20, 46). In the present study, dexamethasone’s effects on skeletal muscle mass and myostatin protein and mRNA concentrations were antagonized by concurrent treatment with RU-486. This suggests that dexamethasone affects myostatin expression predominantly through a glucocorticoid receptor pathway. Although dexamethasone affects myostatin expression predominantly (14, 20, 46). In the present study, dexamethasone thus prevents dexamethasone-induced muscle atrophy and myostatin protein expression.

In a previous study, rats given a single injection of dexamethasone showed increases in myostatin mRNA expression of 60 and 270% 4 and 24 h, respectively, after treatment (23). Our study expands this finding, showing that dexamethasone-induced upregulation of myostatin is not only dose dependent but also time dependent. We found that, although the marked upregulation of myostatin mRNA and protein expression induced by dexamethasone could be seen for 5 days after treatment, this hyperexpression was not sustained by extending the treatment to 10 days (Fig. 2). The changes in myostatin expression coincided with those in muscle weight and MHC II. The majority of muscle loss occurred in the first 5 days of treatment, whereas animals treated for 10 days did not experience significantly greater muscle loss than those treated for 5 days (Table 2). Carlson et al. (6) also reported a significant upregulation of intramuscular myostatin after the first day of hindlimb unloading but a return to basal levels after 3–7 days of hindlimb suspension. Rats given high doses of corticosterone have significantly increased muscle tyrosine levels, an important indicator of net protein degradation (5, 15, 19, 35), after 2–5 days of treatment; however, after 5 days, the changes in tyrosine release are not sustained (5). Glucocorticoids are known to upregulate proteolysis and stimulate the expression of components of the ubiquitin-proteolytic pathways in both skeletal muscle and myocytes (8, 15, 27, 31, 34, 46); however, significant changes in ubiquitin are not observed after long-term glucocorticoid excess (36). The molecular adaptations that prevent continued loss of muscle mass and attenuate increases in myostatin expression during long-term exposure to catabolic stimuli remain unknown.

In addition to multiple GREs, the myostatin promotor contains other elements important for muscle growth. The presence of myocyte enhancer factor-2 and nuclear factor-κB, among others (26), indicates that myostatin is probably regulated not only by glucocorticoids but also by other factors. The role of these putative factors in acute and chronic regulation of myostatin gene expression during illness and other catabolic states remains to be elucidated.

In summary, we have demonstrated that dexamethasone dose- and time-dependently induces loss of body and muscle weights, upregulates intramuscular myostatin protein and mRNA concentrations, and is associated with a decline in MHC II expression. These effects can be blocked by the addition of RU-486, suggesting that myostatin expression is mediated via glucocorticoid receptors. We propose that muscle loss associated with dexamethasone administration is mediated, in part, by the upregulation of myostatin expression through a glucocorticoid receptor-mediated pathway. The speculation that dexamethasone induces muscle loss by upregulating myostatin transcription should now be further tested.

We thank Dr. Wayne Taylor for valuable criticisms in preparation of the manuscript, and Dr. Linda Woodhouse for help with the statistical analysis.

DISCLOSURE

This study was supported by research grants from the Research Center in Minority Institutions (RCMI) for the Center of Urban Research and Education in Diabetes and Metabolism (RR-14166), National Institute of Diabetes and Digestive and Kidney Diseases (2RO1 DK-49296-06 and 1RO1 DK-59627-01), National Institute on Aging (1RO1 AG-14369-01), and RCMI Clinical Research Initiative no. G12 RR-03026-16.

REFERENCES

10. Gardiner PF, Montanaro G, Simpson DR, and Edgerton VR. Effects of glucocorticoid treatment and food restriction on...


